Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mydecine Innovations Group Inc MYCOF


Primary Symbol: C.MYCO

Healthcare Advertising Agencies
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.


CSE:MYCO - Post by User

Mydecine Innovations Group Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(36)
•••
Post by MrVerbatim9800on Jan 14, 2021 10:54am
204 Views
Post# 32293848

The Hault was just about the same news that was released

The Hault was just about the same news that was releasedThis morning...

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

 

 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

DENVER, Jan. 14, 2021 /CNW/ – Mydecine Innovations Group™ (CSE:MYCO)(OTC:MYCOF)(FSE: 0NFA) (”Mydecine” or the ”Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord Genuity” or the “Underwriter”), pursuant to which Canaccord Genuity has agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate ...

 

 

Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .

For further details see:

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Source: MicroSmallCap (Jan 14, 2021 10:40:44 EST)

News by QuoteMedia
www.quotemedia.com
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities